Abstract
To evaluate the clinical effects and safety of mequitazine, we prescribed 6 mg day by for two weeks for 18 patients with nasal allergy. Nasal symptoms and signs, side effects and laboratory data were examined before and after the administration of mequitazine. The results are as follows: 1. Overall effectiveness was 77.8%. 2. Nasal symptoms such as sneezing and rhinorrhea were alleviated but the rate of improvement of nasal blockage was poor. Furthermore, in patients with severe nasal symptoms, a greater alleviation of sneezing and rhinorrhea was observed. 3. Intranasal signs were scarecely improved after the administration of mequitazine. 4. No side effects were observed and there were no marked findings in the laboratory data.
